Alnylam Pharmaceuticals
ALNY
$303.64
+3.78%
Alnylam Pharmaceuticals is a biotechnology company and a pioneer in RNA interference (RNAi) therapeutics, a platform for silencing disease-causing genes. The company is the commercial and scientific leader in this field, with multiple approved products for rare diseases like hATTR amyloidosis, acute hepatic porphyria, and primary hyperoxaluria type 1, and has partnered programs in areas like hypercholesterolemia and hemophilia. The current investor narrative revolves around the company's transition from a development-stage firm to a sustainable commercial enterprise, with intense focus on the growth trajectory of its key products, particularly Amvuttra, and its path to sustained profitability amidst ongoing heavy investment in its robust clinical pipeline.…
ALNY
Alnylam Pharmaceuticals
$303.64
Investment Opinion: Should I buy ALNY Today?
Rating: Hold. The core thesis is that while Alnylam's fundamental transition is promising, the stock requires a period of consolidation and proof of sustained profitability after a severe technical breakdown before warranting a Buy rating, aligning with the cautious stance of the recent Jefferies downgrade.
Supporting evidence includes a reasonable forward P/E of 21.73x based on analyst EPS estimates of $19.43, explosive Q4 revenue growth of 84.95% YoY, strong liquidity with a current ratio of 2.76, and substantial free cash flow generation of $465.38M TTM. However, these positives are counterbalanced by an extreme trailing P/E of 166x, inconsistent quarterly profitability, and a stock price down 33% over six months, deeply underperforming the market.
The thesis would upgrade to Buy on two conditions: 1) a confirmed technical reversal with the stock sustaining a move above its downtrend line and key moving averages, and 2) two consecutive quarters of sustained, GAAP profitability demonstrating the Q4 2025 result was not an outlier. It would downgrade to Sell on a break below the 52-week low of $284.28 on high volume, signaling a failure of support. Relative to its own inflated history and given the current uncertainty, the stock is fairly valued to slightly overvalued, as the forward multiple already embeds significant growth expectations.
Sign up to view all
ALNY 12-Month Price Forecast
The investment stance is Neutral, balancing strong long-term fundamentals against severe near-term technical and sentiment damage. The key is the transition from 'story stock' to 'earnings stock,' which is underway but incomplete. The reasonable forward multiple provides a floor, but the catastrophic price action warns of further downside risk if execution stumbles. Confidence is medium due to the high degree of binary outcomes dependent on quarterly earnings prints. The stance would upgrade to Bullish on a confirmed technical reversal above $350 coupled with a second consecutive profitable quarter. It would downgrade to Bearish on a breakdown below $284 with high volume, indicating institutional capitulation.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Alnylam Pharmaceuticals's 12-month outlook, with a consensus price target around $394.73 and implied upside of +30.0% versus the current price.
Average Target
$394.73
10 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
10
covering this stock
Price Range
$243 - $395
Analyst target range
The stock is covered by 11 analysts, with recent institutional ratings showing a strong bullish bias, including multiple 'Buy' reiterations from firms like HC Wainwright, Chardan Capital, and Needham in early 2026, though one notable downgrade from Jefferies to 'Hold' in March 2026 introduces a note of caution. The consensus is derived from revenue and EPS estimates, with an average revenue forecast of $11.74 billion and an average EPS estimate of $19.43 for the period ahead; the wide range between the low EPS estimate of $17.77 and the high of $23.71 signals significant uncertainty and divergence in modeling the company's future profitability, which is common for commercial-stage biotechs with evolving commercial dynamics and pipeline readouts.
Bulls vs Bears: ALNY Investment Factors
The bull case, supported by explosive revenue growth, a reasonable forward valuation, and strong analyst sentiment, currently holds stronger evidence for long-term investors. However, the bear case presents immediate and severe risks, primarily the stock's catastrophic technical breakdown and the extreme trailing valuation that demands flawless execution. The single most important tension in the investment debate is whether the company's transition to sustained profitability can be achieved smoothly enough to justify its current forward multiple before the technical damage and investor sentiment deteriorate further. The resolution of this profitability consistency will determine if the stock is a deep-value turnaround or a value trap.
Bullish
- Explosive Revenue Growth & Profitability: Q4 2025 revenue surged 84.95% YoY to $1.097B, demonstrating strong commercial traction. The company achieved a trailing net margin of 8.45% and generated $465.38M in free cash flow, signaling a transition to a self-funding, profitable enterprise.
- Attractive Forward Valuation: The forward P/E of 21.73x is reasonable for a commercial-stage biotech leader, especially compared to the extreme trailing P/E of 166x. This suggests the market is pricing in significant earnings growth, with analyst consensus EPS of $19.43 implying substantial profit expansion.
- Strong Analyst Conviction: Coverage by 11 analysts shows a strong bullish bias, with multiple 'Buy' reiterations in early 2026. The average analyst revenue forecast of $11.74B indicates robust confidence in the long-term commercial ramp of Alnylam's RNAi platform.
- Robust Financial Health: The balance sheet is solid with a current ratio of 2.76 and an impressive ROE of 39.76%. This financial strength provides a cushion to fund the robust clinical pipeline without immediate dilution risk.
Bearish
- Extreme Trailing Valuation & High Expectations: The trailing P/E of 166.04x is astronomically high and near the top of its historical range. This leaves no room for earnings disappointment and indicates the market is already pricing in near-perfect execution of future growth.
- Inconsistent Profitability & Earnings Volatility: Despite a profitable Q4, the company posted a net loss of -$66.28M in Q2 2025. This quarterly earnings volatility, typical of biotech, makes sustained profitability uncertain and challenges the forward earnings narrative.
ALNY Technical Analysis
The stock is in a pronounced downtrend, having declined 33.08% over the past six months and 24.54% year-to-date as of the data date. Currently trading at $301.98, the price sits near the lower end of its 52-week range ($284.28 to $495.55), positioning it at approximately 21% of the range's span, which suggests the stock is deeply oversold and may present a value opportunity, though it also risks being a 'falling knife' if the fundamental outlook deteriorates further. Recent momentum shows a stark divergence, with a 0.26% gain over the past month contrasting sharply with the 9.29% loss over three months, indicating a potential stabilization or short-term consolidation after the severe sell-off, though the negative relative strength of -6.05 versus the SPY over one month shows it is still underperforming the broader market. Key technical support is clearly defined at the 52-week low of $284.28, while resistance lies at the recent highs near $495.55; a decisive break below support could trigger another leg down, whereas a sustained move above the downtrend line would be needed to signal a reversal. With a beta of 0.302, the stock has exhibited significantly lower volatility than the market during this period, which is unusual for a biotech but may reflect its transition to a commercial-stage company.
Beta
0.30
0.30x market volatility
Max Drawdown
-42.0%
Largest decline past year
52-Week Range
$283-$496
Price range past year
Annual Return
-0.5%
Cumulative gain past year
| Period | ALNY Return | S&P 500 |
|---|---|---|
| 1m | +0.8% | +4.6% |
| 3m | -5.3% | +12.6% |
| 6m | -33.7% | +10.4% |
| 1y | -0.5% | +27.0% |
| ytd | -24.1% | +11.0% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
ALNY Fundamental Analysis
Revenue growth has been explosive but volatile, with Q4 2025 revenue of $1.097 billion representing an 84.95% year-over-year increase, though this follows a weaker Q2 2025 of $773.7 million; the multi-quarter trend shows significant lumpiness, typical of biotech royalty and collaboration revenue, but the underlying product sales trajectory for GIVLAARI ($160.67M) and ONPATTRO ($70.76M) in the provided segment data indicates commercial execution. The company achieved profitability in recent quarters, with Q4 2025 net income of $186.42 million and a trailing net margin of 8.45%, while gross margin remains robust at 81.77%; however, profitability is inconsistent, as seen in net losses of -$66.28 million in Q2 2025, indicating the path to sustained earnings is still maturing as operating expenses fluctuate with R&D cycles. The balance sheet shows a debt-to-equity ratio of 1.62, indicating moderate leverage, but financial health is supported by strong liquidity with a current ratio of 2.76 and substantial cash generation, evidenced by trailing twelve-month free cash flow of $465.38 million and an ROE of 39.76%, suggesting the company can fund its growth internally while delivering solid returns on equity.
Quarterly Revenue
$1.1B
2025-12
Revenue YoY Growth
+0.84%
YoY Comparison
Gross Margin
+0.75%
Latest Quarter
Free Cash Flow
$465383000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is ALNY Overvalued?
Given the company's positive but modest trailing net income, the primary valuation metric selected is the Price-to-Earnings (P/E) ratio. The trailing P/E is extremely high at 166.04x, while the forward P/E is a much more reasonable 21.73x; this massive gap implies the market is pricing in a significant acceleration in earnings growth and a normalization of profitability from recent quarterly results. Compared to the biotechnology industry, a forward P/E of 21.7x is likely at a premium, though specific industry average data is not provided in the valuation set; this premium would need to be justified by Alnylam's first-mover advantage in RNAi, its commercial portfolio, and its pipeline potential. Historically, the stock's own trailing P/E has swung wildly, from 70.52x at the end of Q4 2025 to much higher levels in prior quarters; the current trailing multiple of 166x is near the top of its recent historical range, suggesting the market is still pricing in very optimistic expectations for future earnings despite the recent price decline, leaving little room for disappointment.
PE
166.0x
Latest Quarter
vs. Historical
High-End
5-Year PE Range -456x~71x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
92.8x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks center on earnings volatility and high fixed costs. Despite a trailing net margin of 8.45%, quarterly results swing wildly from a $186.42M profit in Q4 2025 to a $66.28M loss in Q2 2025, making sustained profitability uncertain. The debt-to-equity ratio of 1.62, while moderate, adds financial rigidity, and the business model remains exposed to lumpy collaboration revenue and heavy, ongoing R&D investment, which consumed $372.22M in the last quarter alone.
Market & Competitive Risks are pronounced given the stock's valuation and sector dynamics. The trailing P/E of 166x represents a massive premium that is highly vulnerable to compression if growth expectations are not met. The stock's beta of 0.302 is deceptively low for a biotech, but its -35.47% YTD underperformance versus the SPY shows it is suffering from severe sector-specific de-rating. Any clinical setbacks in the pipeline or increased competition in rare disease markets could trigger further multiple contraction.
Worst-Case Scenario involves a failure to achieve consistent profitability, leading to a cascade of analyst downgrades from the current bullish consensus. This could break key technical support at the 52-week low of $284.28, potentially revisiting the -42.01% max drawdown level from recent highs. In this adverse scenario, a realistic downside from the current $301.98 price could be -35% to -40%, targeting a range of $180 to $200, as the market reprices the stock for a prolonged period of uncertainty and cash burn, stripping away its growth premium entirely.
FAQ
The key risks are, in order of severity: 1) Valuation & Sentiment Risk: The extreme trailing P/E of 166x leaves no room for error; any earnings disappointment could trigger severe multiple compression. 2) Operational Risk: Quarterly earnings are highly volatile, swinging from a $186M profit to a $66M loss within six months, challenging the path to sustained profitability. 3) Technical Risk: The stock is in a severe downtrend, down 33% in six months and threatening its 52-week low; a break lower could induce panic selling. 4) Competitive/Clinical Risk: The robust pipeline requires continued heavy R&D investment ($372M last quarter), with always-present risk of clinical trial failures.
The 12-month forecast is a wide range reflecting high uncertainty, with three scenarios. The Base Case (50% probability) sees the stock consolidating between $320 and $380 as it proves out its growth story with choppy profitability. The Bull Case (30% probability) targets $450 to $495 on sustained profitability and pipeline successes, reclaiming its prior highs. The Bear Case (20% probability) warns of a drop to $180-$284 if earnings disappoint and the technical breakdown continues. The Base Case is most likely, predicated on the company meeting, but not dramatically exceeding, current analyst expectations for revenue and EPS growth.
ALNY's valuation presents a stark dichotomy: it is extremely overvalued on a trailing basis with a P/E of 166x, but appears reasonably valued on a forward basis at 21.7x P/E. This gap shows the market is paying a premium for expected future earnings growth. Compared to biotech peers, a forward multiple in the low 20s is likely at a premium, justified by its first-mover commercial leadership in RNAi. The valuation implies the market expects near-flawless execution to grow into its earnings estimates. Therefore, it is fairly valued to slightly overvalued relative to the high degree of execution risk still present.
ALNY is a high-risk, high-reward stock that may be a good buy for aggressive, long-term investors who believe in the RNAi platform and can tolerate volatility. Currently rated Hold, it presents a reasonable forward P/E of 21.7x based on strong analyst EPS growth forecasts to $19.43. However, it is not a good buy for short-term traders or risk-averse investors, given its 33% six-month decline, inconsistent profitability, and risk of breaking below its 52-week low of $284. A patient investor might consider initiating a small position on further weakness, with plans to average down, but should wait for a confirmed trend reversal for a larger commitment.
ALNY is strictly suitable for long-term investment with a minimum horizon of 3-5 years. Its value is tied to the long-term commercial ramp of its RNAi platform and pipeline, not short-term trading dynamics. The stock's low beta of 0.302 is misleading; its volatility is driven by binary events like earnings and clinical data, making it poor for short-term trading. It pays no dividend, offering no income component. Investors must be prepared to hold through significant quarterly volatility while the company's earnings profile matures. A short-term view exposes an investor to the high risk of being whipsawed by sentiment shifts around each quarterly report.